Medication Therapy Management With Pharmacogenetic Testing

Duke University

Status: Completed

Conditions: Medication Therapy Management; Pharmacogenetics

Treatments: Other: MTM with PGx

Study type: Interventional

Funder types: Other

Identifiers

NCT01970774

Pro00048123

Details and patient eligibility

About

This study aims to investigate the benefit and feasibility of providing pharmacogenetic (PGx) testing as part of a standard medication therapy management (MTM) session for patients taking multiple medications, a high-risk population for adverse drug reactions and non-response. Research participants will attend two MTM sessions and undergo PGx testing to inform the MTM plan. Participants will also complete 2 surveys pre and post-MTM/PGx testing. Data analysis will assess the impact of MTM/PGx testing on recommendations for drug dosing, clinical outcomes, patient satisfaction, and feasibility of service delivery. Safety issues are minimal with the primary risks being associated with loss of confidentiality, typical discomfort associated with acquiring blood samples, and genetic discrimination.

Enrollment: 30 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• currently prescribed 3 medications, one of which must be simvastatin or clopidogrel
• 18 years of age or older
• English speaking
• patients of Mahesh Patel or William Kraus at Duke Southpoint Clinic

Exclusion criteria

• if patient has ever had MTM or PGx

Trial design

Primary purpose: Supportive Care

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

MTM and PGx

Experimental group

Description:

Participants attend two MTM sessions and have PGx testing

Treatment:

Other: MTM with PGx